SBEC Systems (517360)

Turnaround

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Current Price₹44.17
Market Cap₹46.49 Cr
P/E Ratio16.11
ROCE50.83%
ROE2,715.29%
Dividend Yield0%
Profit Growth-151.79%
Debt/Equity
Sales Growth3.85%
52-Week Range₹15.25 — ₹44.17
SectorCommercial Services & Supplies
Book Value₹0.04

Strengths

Concerns

AI Analysis

At ₹44.17, SBEC Systems has a market capitalisation of ₹46 Cr. That is a very small business, and in trading and distribution, small is not automatically wonderful. My first question is always: what gives this distributor a durable competitive advantage? Nothing in these numbers suggests a moat. Sales growth is a weak 3.85%, and the latest quarter brought in only ₹1 Cr of revenue. The profit picture is worse: profit growth is -151.79%, and the latest quarter shows a net profit of ₹-0 Cr. Piotroski's F-score of 4/9 is a warning sign, not a confirmation. The balance sheet is peculiar. Book value is just ₹0.04 per share, so a P/B of 1,104 times means equity is almost nonexistent. That makes the ROE of 2,715% and even the ROCE of 50.83% statistical illusions—they are produced by dividing small profits by an even smaller base. Graham would have called this an absence of asset backing, not a sign of strength. There is no dividend, promoter holding is not disclosed, and the PEG ratio of 4.18 tells me the current price already exceeds any reasonable growth justification. At 16.11 times earnings, I am willing to pay a fair price for a wonderful business, but this is not a wonderful business. The stock is at the top of its 52-week range (₹15.25–₹44.17), so market sentiment is positive. Sentiment, however, is not safety. With collapsing profits, a tiny equity cushion, and no clear moat, I cannot find a margin of safety. If this is meant to be a turnaround, I want proof of improving results before I risk capital. For now, I would rather watch from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer